CYP2C19 and Stroke: The aim of present study was to investigate the effectiveness of antiplatelet agents for the secondary prevention of stroke according to CYP2C19 genotypes in IS patients on the basis of our previous randomized-controlled trial of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis (LAA) stroke [18].